1. Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials

   • Yu Fujiwara
   • Nobuyuki Horita
   • Matthew D. Galsky

   Review Article 26 April 2022 Pages: 2837 - 2848

   

2. Natural killer cells and acute myeloid leukemia: promises and challenges

   • Shayan Rahmani
   • Niloufar Yazdanpanah
   • Nima Rezaei

   Review Article 31 May 2022 Pages: 2849 - 2867

   

3. Opening up new VISTAs: V-domain immunoglobulin suppressor of T cell activation (VISTA) targeted near-infrared photoimmunotherapy (NIR-PIT) for enhancing host immunity against cancers

   • Hiroaki Wakiyama
   • Aki Furusawa
   • Hisataka Kobayashi

   Original Article 21 April 2022 Pages: 2869 - 2879

   

4. Tcf-1 protects anti-tumor TCR-engineered CD8⁺ T-cells from GzmB mediated self-destruction

   • Brendan Zangari
   • Takemasa Tsuji
   • Kunle Odunsi

   Original Article Open access 23 April 2022 Pages: 2881 - 2898

   

5. Correction to: Tcf‑1 protects anti‑tumor TCR‑engineered CD8⁺ T‑cells from GzmB mediated self‑destruction

   • Brendan Zangari
   • Takemasa Tsuji
   • Kunle Odunsi

   Correction Open access 06 June 2022 Pages: 2899 - 2899

6. Immune activation of the monocyte-derived dendritic cells using patients own circulating tumor cells

   • Katarina Kolostova
   • Eliska Pospisilova
   • Vladimir Bobek

   Original Article 26 April 2022 Pages: 2901 - 2911

   

7. First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience

   • Stefanie Kreutmair
   • Dietmar Pfeifer
   • Michael Lübbert

   Original Article Open access 27 April 2022 Pages: 2913 - 2928

   

8. Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity

   • Nishant Chovatiya
   • Kawaljit Kaur
   • Anahid Jewett

   Original Article 04 May 2022 Pages: 2929 - 2941

   

9. Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model

   • Bindu Varghese
   • Lydia Lynch
   • Mark A. Exley

   Original Article 06 May 2022 Pages: 2943 - 2955

   

10. Targeting tumor extracellular matrix activates the tumor-draining lymph nodes

    • Alexander J. Najibi
    • Ting-Yu Shih
    • David J. Mooney

    Original Article 07 May 2022 Pages: 2957 - 2968

    

11. In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4⁺ and CD8⁺ T-cell epitopes for cancer immunotherapy

    • Xu-Dong Tang
    • Kui-Lin Lü
    • Lei Chen

    Original Article 12 May 2022 Pages: 2969 - 2983

    

12. Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies

    • V. Moreno
    • E. Calvo
    • M. Wermke

    Original Article 21 May 2022 Pages: 2985 - 2998

    

13. Circulating extracellular vesicles carrying Firmicutes reflective of the local immune status may predict clinical response to pembrolizumab in urothelial carcinoma patients

    • Kentaro Jingushi
    • Atsunari Kawashima
    • Norio Nonomura

    Original Article 22 May 2022 Pages: 2999 - 3011

    

14. High DKK3 expression related to immunosuppression was associated with poor prognosis in glioblastoma: machine learning approach

    • Myung-Hoon Han
    • Kyueng-Whan Min
    • Mi Jung Kwon

    Original Article Open access 23 May 2022 Pages: 3013 - 3027

    

15. Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer

    • Sung Eun Lee
    • Gun-Young Jang
    • Tae Heung Kang

    Original Article 24 May 2022 Pages: 3029 - 3042

    

16. Functional expression of CD73 on human natural killer cells

    • Andrea M. Chambers
    • Jiao Wang
    • Sandro Matosevic

    Original Article 25 May 2022 Pages: 3043 - 3056

    

17. Tumor-derived IL-8 facilitates lymph node metastasis of gastric cancer via PD-1 up-regulation in CD8⁺ T cells

    • Xiang Li
    • Jing Zhai
    • Lizong Shen

    Original Article Open access 28 May 2022 Pages: 3057 - 3070

    

18. Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis

    • Haizhu Chen
    • Yu Feng
    • Yuankai Shi

    Original Article 01 June 2022 Pages: 3071 - 3085

    

19. Checkpoint-inhibitor induced Polyserositis with Edema

    • Sarah Zierold
    • Larissa Semra Akcetin
    • Lucie Heinzerling

    Research Report Open access 16 May 2022 Pages: 3087 - 3092

    

20. Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study

    • Pascale Palassin
    • Alexandre T. J. Maria
    • Jean-Luc Faillie

    Research Report 26 May 2022 Pages: 3093 - 3097

21. Near-infrared photoimmunotherapy induced tumor cell death enhances tumor dendritic cell migration

    • Taiki Moriya
    • Mayuko Hashimoto
    • Michio Tomura

    Research Report 28 May 2022 Pages: 3099 - 3106